Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640185 | 0.90 | CSNK1D (0.52) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL1639870 | 0.87 | CSNK1D (0.68) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL15203489 | 0.86 | CSNK1D (0.54) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL1640205 | 0.85 | CSNK1D (0.57) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL1640975 | 0.85 | CSNK1D (0.69) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL15203534 | 0.83 | CSNK1D (0.49) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL1640703 | 0.83 | MAPK14 (0.53) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL15203509 | 0.83 | MAPK14 (0.58) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL15203563 | 0.83 | CSNK1D (0.53) | CSNK1DCSNK1EEGFRMAPK14MAPK13 | |
| SCHEMBL15203570 | 0.83 | CSNK1D (0.49) | CSNK1DCSNK1EEGFRMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | CSNK1A1, CSNK1A1L, CSNK1G1 | CSNK1D 12/4885CSNK1E 5/4885EGFR 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.